Early research suggests Merck cancer drug may target dormant HIV - Hindustan Times
An international research collaboration said it has found evidence that pembrolizumab can reverse HIV latency - the ability for the virus to "hide" inside cells of people living with HIV on antiretroviral therapy. | Health
Researchers studying Merck & Co Inc's cancer drug Keytruda for HIV patients who also have cancer say the immunotherapy may help displace the virus from human immune cells, offering an intriguing … [+1948 chars]
Read More
Other Stories in Health
- 3 nutrients that work best to improve memory and intelligence
- Can Combined Renal Function Markers & Blood Lipid Levels Predict PE?
- Exclusive: World Cancer Day 2025 - 'India Will See Rise Of 12% To 18% In Cancer Cases', Why Are People More at Risk In Recent Times
- How My Ex and I Created a Beautiful Friendship
- Weekly Horoscope For January 27-February 2, From The AstroTwins
- EMCrit 393 – CV-EMCrit – Inotrope Basics Part 1
- How to ace the perfect tri-colour makeup on Republic Day 2025
- Immune environment found to influence success of leukemia immunotherapy
- University Hospitals introduces endoscopic spine surgery for back pain patients with herniated discs
.png)
